203 related articles for article (PubMed ID: 25259517)
1. Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists.
Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
PLoS One; 2014; 9(9):e106072. PubMed ID: 25259517
[TBL] [Abstract][Full Text] [Related]
2. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries.
Bazargani YT; Ugurlu M; de Boer A; Leufkens HGM; Mantel-Teeuwisse AK
BMC Cardiovasc Disord; 2018 Jun; 18(1):126. PubMed ID: 29940880
[TBL] [Abstract][Full Text] [Related]
3. Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries.
Samukange WT; Gardarsdottir H; Leufkens HGM; Mantel-Teeuwisse AK
Transfus Med Rev; 2020 Apr; 34(2):94-100. PubMed ID: 31761652
[TBL] [Abstract][Full Text] [Related]
4. Selection of oncology medicines in low- and middle-income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
Ann Oncol; 2014 Jan; 25(1):270-6. PubMed ID: 24356638
[TBL] [Abstract][Full Text] [Related]
5. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.
Chow CK; Ramasundarahettige C; Hu W; AlHabib KF; Avezum A; Cheng X; Chifamba J; Dagenais G; Dans A; Egbujie BA; Gupta R; Iqbal R; Ismail N; Keskinler MV; Khatib R; Kruger L; Kumar R; Lanas F; Lear S; Lopez-Jaramillo P; McKee M; Mohammadifard N; Mohan V; Mony P; Orlandini A; Rosengren A; Vijayakumar K; Wei L; Yeates K; Yusoff K; Yusuf R; Yusufali A; Zatonska K; Zhou Y; Islam S; Corsi D; Rangarajan S; Teo K; Gerstein HC; Yusuf S;
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):798-808. PubMed ID: 30170949
[TBL] [Abstract][Full Text] [Related]
6. Essential medicines for breast cancer in low and middle income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
BMC Cancer; 2015 Aug; 15():591. PubMed ID: 26283654
[TBL] [Abstract][Full Text] [Related]
7. Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study.
Sarayani A; Rashidian A; Gholami K
BMJ Open; 2014 Oct; 4(10):e005859. PubMed ID: 25324322
[TBL] [Abstract][Full Text] [Related]
8. Essential diabetes medicines and health outcomes in 127 countries.
Budhram D; Benipal S; Bilimoria K; Maraj D; Wang R; Persaud N
Diabetes Obes Metab; 2021 May; 23(5):1121-1128. PubMed ID: 33417268
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study.
Adekoya I; Maraj D; Steiner L; Yaphe H; Moja L; Magrini N; Cooke G; Loeb M; Persaud N
Lancet Infect Dis; 2021 Oct; 21(10):1429-1440. PubMed ID: 34332706
[TBL] [Abstract][Full Text] [Related]
10. Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income Countries.
Barr R; Robertson J
Pediatr Blood Cancer; 2016 Feb; 63(2):287-91. PubMed ID: 26375626
[TBL] [Abstract][Full Text] [Related]
11. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list.
Naicker I; Suleman F; Perumal-Pillay VA
J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421
[TBL] [Abstract][Full Text] [Related]
12. Insights from the WHO and National Lists of Essential Medicines: Focus on Pediatric Diabetes Care in Africa.
Rowlands A; Ameyaw E; Rutagarama F; Dipesalema J; Majaliwa ES; Mbogo J; Ogle GD; Chanoine JP
Horm Res Paediatr; 2018; 90(2):82-92. PubMed ID: 30048982
[TBL] [Abstract][Full Text] [Related]
13. Essential medicines for COPD and asthma in low and middle-income countries.
Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
Thorax; 2014 Dec; 69(12):1149-51. PubMed ID: 24590803
[TBL] [Abstract][Full Text] [Related]
14. Essential medicines availability is still suboptimal in many countries: a scoping review.
Mahmić-Kaknjo M; Jeličić-Kadić A; Utrobičić A; Chan K; Bero L; Marušić A
J Clin Epidemiol; 2018 Jun; 98():41-52. PubMed ID: 29452222
[TBL] [Abstract][Full Text] [Related]
15. The role of government agencies and other actors in influencing access to medicines in three East African countries.
Odoch WD; Dambisya Y; Peacocke E; Sandberg KI; Hembre BSH
Health Policy Plan; 2021 Apr; 36(3):312-321. PubMed ID: 33569583
[TBL] [Abstract][Full Text] [Related]
16. A comparison of national essential medicines lists in the Americas.
Steiner L; Maraj D; Woods H; Jarvis J; Yaphe H; Adekoya I; Bali A; Persaud N
Rev Panam Salud Publica; 2020; 44():e5. PubMed ID: 31998375
[TBL] [Abstract][Full Text] [Related]
17. WHO essential medicines policies and use in developing and transitional countries: an analysis of reported policy implementation and medicines use surveys.
Holloway KA; Henry D
PLoS Med; 2014 Sep; 11(9):e1001724. PubMed ID: 25226527
[TBL] [Abstract][Full Text] [Related]
18. Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study.
Taglione MS; Persaud N
BMJ Open; 2021 Aug; 11(8):e045262. PubMed ID: 34380717
[TBL] [Abstract][Full Text] [Related]
19. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
[TBL] [Abstract][Full Text] [Related]
20. Challenges in managing infections among pediatric cancer patients: Suboptimal national essential medicines lists for low and middle income countries.
Kirby J; Ojha RP; Johnson KM; Bittner EC; Caniza MA
Pediatr Blood Cancer; 2015 Feb; 62(2):204-207. PubMed ID: 25307693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
